Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study

Bibliographic Details
Main Author: Jarimba, Roberto Saldanha
Publication Date: 2021
Other Authors: Eliseu, Miguel Nobre, Pedroso Lima, João, Quaresma, Vasco, Moreira, Pedro, Nunes, Pedro Coelho, Silva, Edgar Tavares da, Figueiredo, Arnaldo José
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://hdl.handle.net/10316/100893
https://doi.org/10.4081/aiua.2021.4.393
Summary: Prostate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer but there is a lack of quality evidence regarding which is associated with better outcomes and who would benefit the most with one or another of these drugs.
id RCAP_68a68d56b4f5ac05a245632bf90d89ba
oai_identifier_str oai:estudogeral.uc.pt:10316/100893
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective studyProstate cancerAbirateroneEnzalutamideCastration-resistantAbiraterone AcetateHumansMaleProspective StudiesRetrospective StudiesTreatment OutcomeAntineoplastic AgentsProstatic Neoplasms, Castration-ResistantProstate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer but there is a lack of quality evidence regarding which is associated with better outcomes and who would benefit the most with one or another of these drugs.2021-12-20info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://hdl.handle.net/10316/100893https://hdl.handle.net/10316/100893https://doi.org/10.4081/aiua.2021.4.393eng2282-41971124-3562Jarimba, Roberto SaldanhaEliseu, Miguel NobrePedroso Lima, JoãoQuaresma, VascoMoreira, PedroNunes, Pedro CoelhoSilva, Edgar Tavares daFigueiredo, Arnaldo Joséinfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2022-07-19T20:37:52Zoai:estudogeral.uc.pt:10316/100893Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T05:50:04.691575Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
title Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
spellingShingle Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
Jarimba, Roberto Saldanha
Prostate cancer
Abiraterone
Enzalutamide
Castration-resistant
Abiraterone Acetate
Humans
Male
Prospective Studies
Retrospective Studies
Treatment Outcome
Antineoplastic Agents
Prostatic Neoplasms, Castration-Resistant
title_short Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
title_full Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
title_fullStr Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
title_full_unstemmed Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
title_sort Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
author Jarimba, Roberto Saldanha
author_facet Jarimba, Roberto Saldanha
Eliseu, Miguel Nobre
Pedroso Lima, João
Quaresma, Vasco
Moreira, Pedro
Nunes, Pedro Coelho
Silva, Edgar Tavares da
Figueiredo, Arnaldo José
author_role author
author2 Eliseu, Miguel Nobre
Pedroso Lima, João
Quaresma, Vasco
Moreira, Pedro
Nunes, Pedro Coelho
Silva, Edgar Tavares da
Figueiredo, Arnaldo José
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Jarimba, Roberto Saldanha
Eliseu, Miguel Nobre
Pedroso Lima, João
Quaresma, Vasco
Moreira, Pedro
Nunes, Pedro Coelho
Silva, Edgar Tavares da
Figueiredo, Arnaldo José
dc.subject.por.fl_str_mv Prostate cancer
Abiraterone
Enzalutamide
Castration-resistant
Abiraterone Acetate
Humans
Male
Prospective Studies
Retrospective Studies
Treatment Outcome
Antineoplastic Agents
Prostatic Neoplasms, Castration-Resistant
topic Prostate cancer
Abiraterone
Enzalutamide
Castration-resistant
Abiraterone Acetate
Humans
Male
Prospective Studies
Retrospective Studies
Treatment Outcome
Antineoplastic Agents
Prostatic Neoplasms, Castration-Resistant
description Prostate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer but there is a lack of quality evidence regarding which is associated with better outcomes and who would benefit the most with one or another of these drugs.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-20
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10316/100893
https://hdl.handle.net/10316/100893
https://doi.org/10.4081/aiua.2021.4.393
url https://hdl.handle.net/10316/100893
https://doi.org/10.4081/aiua.2021.4.393
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2282-4197
1124-3562
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833602489193070592

Similar Items